Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Sponsor: M.D. Anderson Cancer Center
Summary
This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.
Official title: Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed by Rituximab in Hairy Cell Leukemia
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2004-06-10
Completion Date
2027-06-30
Last Updated
2025-12-22
Healthy Volunteers
No
Interventions
Cladribine
Given IV
Laboratory Biomarker Analysis
Correlative studies
Rituximab
Given IV
Locations (1)
M D Anderson Cancer Center
Houston, Texas, United States